华东医药股价小幅调整 专利纠纷影响市场关注

Core Viewpoint - Huadong Medicine's stock price experienced a decline of 1.32% on August 8, closing at 42.47 yuan, with a trading volume of 355 million yuan [1] Company Overview - Huadong Medicine operates in three main sectors: pharmaceutical manufacturing, pharmaceutical commerce, and medical aesthetics [1] - The company's core products include Bailin capsules and Indomethacin tablets, with a focus on oncology, diabetes, and immunosuppressants [1] - The wholly-owned subsidiary, Sino-American Huadong, holds a patent for the crystal form of Indomethacin tablets, which is protected until 2040 [1] Recent Developments - Sino-American Huadong is actively defending its patent rights for Indomethacin tablets, resulting in seven pharmaceutical companies being suspended from purchasing the product due to patent disputes [1] - The National Intellectual Property Administration has ruled to maintain the validity of the involved patents against several invalidation requests [1] - Due to the patent disputes, Indomethacin tablets were not included in the 11th batch of national drug procurement [1] Financial Activity - On August 8, Huadong Medicine saw a net outflow of 4.4782 million yuan in principal funds, while the cumulative net inflow over the past five days reached 9.757 million yuan [1]